Immunotherapy and its research progress of metastatic castration resistant prostate cancer
10.3760/cma.j.cn112330-20191107-00498
- VernacularTitle:转移性去势抵抗性前列腺癌免疫治疗的现状和研究进展
- Author:
Shangrong WU
1
;
Ranlu LIU
Author Information
1. 天津医科大学第二医院泌尿外科 天津市泌尿外科研究所 300211
- From:
Chinese Journal of Urology
2020;41(8):637-640
- CountryChina
- Language:Chinese
-
Abstract:
The ideal immunotherapy should be highly lethal to the tumor and harmless to the body, therefore it’s applied to the highly fatal metastatic castration-resistant prostate cancer. Immunotherapy for prostate cancer currently includes vaccine therapy, immunocheckpoint blocking therapy, immunomodulator therapy, and combination therapy, which treat prostate cancer through different immune mechanisms. A vaccine called Sipuleucel-T has been approved by the Food and Drug Administration to treat metastatic castration-resistant prostate cancer, while research on other immune drugs is ongoing. This article reviews the current status and recent progress of various immunotherapies for metastatic castration-resistant prostate cancer.
